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DObjectives: We examined the early and midterm outcomes of homograft use in reoperative aortic root and
proximal aortic surgery for endocarditis and estimated the associated risk of postoperative reinfection.
Methods: From January 2001 to January 2014, 355 consecutive patients underwent reoperation of the proximal
thoracic aorta. Thirty-nine patients (10.9%; mean age, 55.4 13.3 years) presented with active endocarditis; 30
(76.9%) had prosthetic aortic root infection with or without concomitant ascending and arch graft infection, and
9 (23.1%) had proximal ascending aortic graft infection with or without aortic valve involvement. Sixteen
patients (41.0%) had genetically triggered thoracic aortic disease. Twelve patients (30.8%) had more than 1
prior sternotomy (mean, 2.4  0.6).
Results: Valved homografts were used to replace the aortic root in 29 patients (74.4%); nonvalved homografts
were used to replace the ascending aorta in 10 patients (25.6%). Twenty-five patients (64.1%) required
concomitant proximal arch replacement with a homograft, and 2 patients (5.1%) required a total arch homo-
graft. Median cardiopulmonary bypass, cardiac ischemia, and circulatory arrest times were 186 (137-253)
minutes, 113 (59-151) minutes, and 28 (16-81) minutes. Operative mortality was 10.3% (n ¼ 4). The rate of
permanent stroke was 2.6% (n ¼ 1); 3 additional patients had transient neurologic events. One patient (1/35,
2.9%) returned with aortic valve stenosis 10 years after the homograft operation. During the follow-up period
(median, 2.5 years; range, 1 month to 12.3 years), no reinfection was reported, and survival was 65.7%.
Conclusions: This is one of the largest North American single-center series of homograft use in reoperations on
the proximal thoracic aorta to treat active endocarditis. In this high-risk population, homograft tissue can be used
with acceptable early and midterm survival and a low risk of reinfection. When necessary, homograft tissue may
be extended into the distal ascending and transverse aortic arch, with excellent results. These patients require
long-term surveillance for both infection and implant durability. (J Thorac Cardiovasc Surg 2014;148:989-94)Surgery for active infective endocarditis carries significant
mortality. Several specific factors, including whether the
patient has native or prosthetic valve infection, abscess
formation, or root destruction, can significantly affect the
outcome. Reoperation for aortic root infection is technically
challenging and has been associated with mortality of up to
39%.1,2 Homograft aortic root replacement for infective
native or prosthetic endocarditis has been described with
reasonable results in Europe and Japan, including low
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The Journal of Thoracic and Camortality.3-5 From centers in the United States, there is a
paucity of reports regarding complex aortic root
reconstruction with a homograft for active endocarditis,
specifically after previous repair of the root and ascending
aorta. Also, there are no extensive data on longer-term out-
comes or reinfection rate. Therefore, we report our 12-year
experience with these complex, high-risk procedures.
METHODS
Between January 2001 and January 2014, 355 consecutive patients
underwent reoperation on the proximal aorta. Data were collected from a
prospectively maintained database. Approval of the study was obtained
from Baylor College of Medicine’s institutional review board. Thirty-nine
(10.9%) of these patients (mean age, 55.4  13.3 years; 34 [87.2%] were
male) presented with active infection involving their prosthetic aortic
root, prior ascending or arch graft, or both. The majority of these patients
were referred from outside facilities and had already been treated with
antibiotics for an extensive period. While in the hospital, they continued
to receive antibiotics as indicated by current or previous cultures.
Patient characteristics and demographics are outlined in Table 1. The
postoperative outcomes assessed included early neurologic events, renal
insufficiency necessitating hemodialysis, hospital length of stay, early and
late reinfection rate, early and midterm survival, and operative mortality.
Operative Details
All patients were treated with surgical implantation of a cryopreserved
homograft conduit (Life Net Health Bio-Implants Division, Virginia Beach,rdiovascular Surgery c Volume 148, Number 3 989
TABLE 1. Preoperative characteristics and demographics of 39 patients who underwent reoperative aortic root and proximal aortic surgery for
endocarditis
All patients
(N ¼ 39)
Valved homografts
(n ¼ 29)
Nonvalved homografts
(n ¼ s10) P value
Age (y) 55.4  13.3 53.3  13.6 61.6  11.4 .0931
Male gender 34 (87.2) 24 (82.8) 10 (100) .302
>1 previous sternotomy 12 (30.8) 10 (34.5) 2 (20.0) .693
Preoperative hypertension 32 (82.0) 24 (82.7) 8 (80.0) 1.00
Prior or current smoker 23 (60.5) 19 (65.5) 4 (44.4) .436
Congestive heart failure on admission 22 (56.4) 18 (66.7) 4 (40.0) .258
Genetically triggered thoracic aortic disease 16 (41.0) 13 (44.8) 3 (30.0) .353
Prior neurologic event (stroke or TIA) 8 (20.5) 7 (24.1) 1 (10.0) .653
Chronic obstructive pulmonary disease 7 (17.9) 6 (20.7) 1 (10.0) .653
Preoperative renal insufficiency 7 (17.9) 6 (20.7) 1 (10.0) .653
Preoperative atrial fibrillation 6 (15.4) 4 (13.8) 2 (20.0) .636
Previous operations
Aortic root and ascending aortic replacement 21 (53.8) 20 (69.0) 1 (10.0)
Ascending aortic replacement only 7 (17.9) 1 (3.5) 6 (10.0)
Aortic valve replacement only 6 (15.4) 6 (20.7) —
Supracoronary ascending graft with aortic valve replacement 5 (12.8) 2 (6.9) 3 (30.0)
Values are number (percentage) for binary variables and mean ( standard deviation) or median (interquartile range) for continuous variables. Tests performed were the Fisher
exact test for binary variables and the Student t test or Wilcoxon rank-sum test for continuous variables, as appropriate. TIA, Transient ischemic attack.
TABLE 2. Intraoperative data (N ¼ 39)
Cannulation
Axillary 25 (64.1)
Femoral 7 (18.0)
Direct aortic 5 (12.8)
Innominate 2 (5.1)
Procedures/reoperations
Valved homografts 29 (74.3)
Cabrol/hemi-Cabrol or SVG to RCA or LAD 21 (72.4)
Nonvalved homografts 10 (25.6)
Proximal arch replacement 25 (64.1)
Total arch replacement 2 (5.1)
Mitral valve repair 2 (5.1)
Need for IABP 4 (10.2)
Need for ECMO 3 (7.7)
Cardiopulmonary bypass time (min) 186 (137-253)
Cardiac ischemia time (min) 113 (59-151)
Circulatory arrest time (min)* 28 (16-81)
Antegrade cerebral perfusion time (min)y 28 (16.5-73)
Hospital stay (d) 20 (13-35)
Values are number (percentage) for binary variables or median (interquartile range)
for continuous variables. ECMO, Extracorporeal membrane oxygenation; IABP,
intra-aortic balloon pump; LAD, left anterior descending artery; RCA, right coronary
artery; SVG, saphenous vein graft. *n ¼ 27. yn ¼ 24.
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DVa). Twelve patients (30.8%) hadmore than 1 prior sternotomy. Cardiopul-
monary bypass inflow was established by cannulating the right axillary ar-
tery in 25 patients (64.1%), the femoral artery in 7 patients (17.9%), the
aorta in 5 patients (12.8%), and the innominate artery in 2 patients
(5.1%). Twenty-seven patients (69.2%) underwent hypothermic circula-
tory arrest (temperature 20C-24C) for concomitant proximal arch or total
arch reconstruction; all except 3 received unilateral or bilateral antegrade
cerebral perfusion. The patients who required a valved homograft
(n¼ 29, 73.4%) had aortic root abscesses. The abscess cavity and the aortic
annulus were aggressively debrided, and all infected and devitalized tissue
was removed. Specific attentionwas paid to removing all residual prosthetic
material, including previously placed pledgets, Dacron graft, and prosthetic
valve annular cloth. Any structural cardiac defects resulting from extension
of an infected process or from necessary thorough debridement were re-
pairedwith bovine pericardium,whichwas used to patch residual periannu-
lar abscess cavities in 2 patients. Perforation of the anterior leaflet of the
mitral valve was repaired primarily in 2 patients: 1 who required complete
resection of the P2 leaflet for perforation and 1 who required excision of
vegetation from the anterior leaflet (Table 2).
In the implantation of valved root homograft conduits, the proximal
suture line of the trimmed cryopreserved homograft was constructed
with continuous 2-0 or 3-0 Prolene suture and, when necessary, reinforced
with pericardial pledgets. In 14 patients (50%), the coronary ostia were
reimplanted as buttons with 5-0 or 6-0 running Prolene. In patients in
whom the coronary buttons could not be mobilized (n ¼ 31, 79.5%)
because of extensive scar tissue, an interposition graft of autologous
saphenous vein was placed between the homograft and the coronary artery
(left or right) origin. In only 1 patient, an 8-mm Dacron graft was attached
to the left main coronary button (Table 2).
For the distal anastomosis and arch repair, nonvalved homografts were
used in 10 patients (25.6%) to replace the ascending aorta (Table 2). The
distal anastomosis of the homograft conduit to the native aorta was
performed with running 3-0 or 4-0 Prolene. If the proximal or the total
arch needed replacement, a second additional segment of nonvalved
homograft tissuewas used when necessary to extend the length of the initial
root in cases in which the valved homograft root was not long enough to
replace the entire proximal or total arch. With regard to the arch vessels,
an island anastomosis was performed with 4-0 or 5-0 Prolene suture.
Intraoperative cultures were sent for microbiologic analysis.990 The Journal of Thoracic and Cardiovascular SurgPostoperative Care and Follow-up
Intravenous antibiotics were continued for approximately 4 to 6
weeks. The specific regimen depended on the patient’s preoperative and
intraoperative culture results. Patients were discharged with a peripher-
ally inserted central catheter line for administering the intravenous
antibiotics. Late survival and morbidities were determined by clinical
follow-up, direct patient inquiry, and survey of the Social Security Death
Index. Echocardiographic data were examined to access homograft per-
formance. The median follow-up period was 2.5 years (range, 1 month
to 12.3 years).ery c September 2014
TABLE 3. Postoperative complications (N ¼ 38)
Operative mortality* 4 (10.2)
Ventilatory support>48 h 21 (55.3)
Atrial fibrillation 9 (23.7)
Postoperative renal insufficiency (permanent or transient) 9 (23.7)
Tracheostomy 8 (21.0)
Pacemaker 6 (15.4)
Deep vein thrombosis 5 (13.2)
Neurologic events
Permanent stroke 1 (2.6)
Temporary neurologic deficit 3 (7.9)
Preventza et al Acquired Cardiovascular DiseaseStatistical Analysis
Continuous variables were summarized and presented as mean
( standard deviation) when normally distributed and median (interquartile
range) when non-normally distributed. Associations between the use
of a valved homograft and the outcomes (in-hospital mortality and
postoperative neurologic deficit) were tested with the Student t test or
Wilcoxon rank-sum test for normally and non-normally distributed data,
respectively. Binary variables were tabulated, and associations were
measured with the Pearson chi-square or, when cell sizes were small, the
Fisher exact test. Survival functions were estimated by using the
Kaplan–Meiermethod.All analyseswere performedwithStata IC13.1 (Stata
Statistical Software: Release 13; StataCorp LP, College Station, Tex).Reoperation for bleeding 3 (7.9)
Myocardial infarction 1 (2.6)
Values are number (percentage). *N ¼ 39 (1 intraoperative death).
A
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DRESULTS
Operative Mortality
Operative mortality was 10.3% (n ¼ 4). One death
(n ¼ 1, 2.6%) was intraoperative in a patient with Marfan
syndrome with 2 prior sternotomies for root and ascending
graft replacement. Two of the other patients had a compli-
cated postoperative course and required extracorporeal
membrane oxygenation for hemodynamic instability and
inability to ventilate. These patients developed multiorgan
failure, and the families withdrew support on postoperative
days 11 and 43. The last patient who died had 2 prior
sternotomies for aortic valve replacement, ascending aortic
graft placement, and coronary artery bypass grafting. This
patient had a prolonged postoperative course that included
respiratory failure that necessitated extracorporeal
membrane oxygenation and renal failure from which he
recovered. The patient received a new dual pacemaker on
postoperative day 29 and collapsed a few hours later.
Despite cardiopulmonary resuscitation, the patient died.Neurologic Events
One permanent stroke (n¼ 1, 2.6%) was observed among
the survivors. The stroke occurred in the left middle cerebral
artery territory, causing right hemiplegia. The patient was
transferred to an extended-care facility and died 4 years
later. Transient neurologic events occurred in 3 patients, 2
of whom fully recovered. The third patient recovered suc-
cessfully from the event but had a prolonged, complicated
postoperative course and died 43 days postoperatively.FIGURE 1. Kaplan–Meier survival curve among survivors (n ¼ 35).Long-Term Complications Requiring Operation
Among the postdischarge survivors (n ¼ 34; Figure 1), 1
patient (n ¼ 1, 2.9%), who had Marfan syndrome, returned
10 years later with structural degeneration of the homograft
and aortic stenosis. The homograft was removed, and a
biologic valve and supracoronary Dacron graft were
placed. Table 3 outlines all of the short- and long-term
postoperative complications that occurred in our series. In
univariate analysis, none of the various preoperative, intra-
operative, and postoperative variables we examined was
predictive of either operative mortality or postoperative
neurologic deficit (Table 4).The Journal of Thoracic and CaDISCUSSION
Our study represents a 12-year, single-center experience
in a group of high-risk patients with endocarditis whose
aortic root or ascending aorta and aortic arch were re-
placed with cryopreserved homografts. Six of the patients
in this series had previously undergone aortic valve
replacement only, and all 6 presented with perivalvular ab-
scess or dehiscence. The remainder had undergone
ascending graft replacement with or without aortic valve
or total aortic root replacement. There is no evidence in
the literature that clearly supports any particular choice
of aortic root conduit or valve for patients with prosthetic
aortic valve or root endocarditis.5-10 The theoretic
advantage of the homograft is resistance to infection
because the graft is biologic and contains no artificial
material.11 Experienced centers have chosen to use other
prosthetic materials because homografts are not always
immediately available and present significant technical
challenges when reoperation is necessary for degeneration
and calcification.7
Meticulous debridement and extirpation of all infected
tissues can be even more important than the choice ofrdiovascular Surgery c Volume 148, Number 3 991
TABLE 4. Univariate analysis and association with in-hospital
mortality and postoperative neurologic deficit
Operative
mortality
P value
Postoperative
neurologic
deficit P value
Age (y) .7506 .306
Gender 1.00 .517
Genetic tissue disorders 1.00 .557
Preoperative hypertension 1.00 1.00
Congestive heart failure on admission .6 1.00
COPD .56 1.00
Preoperative stroke .502 1.00
Preoperative TIA 1.00 1.00
Prior neurologic deficit 1.00 .56
Preoperative renal failure .563 .147
Valved homograft 1.00 1.00
Nonvalved homograft 1.00 1.00
Proximal or total arch replacement .292 1.00
Circulatory arrest time (min)* .1941 .1847
Antegrade cerebral perfusion (min)y .3134 .2932
Cardiopulmonary bypass time (min) .4874 .2343
Cardiac ischemia (min) .8169 .3294
Postoperative neurologic deficitz .291 —
Pacemakerz 1.00 1.00
Reoperation for bleedingz 1.00 .291
Ventilation>48 hz .238 .613
Postoperative atrial fibrillationz 1.00 .233
Values are number (percentage) for binary variables and mean ( standard deviation)
or median (interquartile range) for continuous variables. COPD, Chronic obstructive
pulmonary disease; TIA, transient ischemic attack. *n¼ 27. yn¼ 24. zn¼ 38 (1 intra-
operative death).
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Dprosthetic valve.12 In addition to debriding the abscess cav-
ities, it is our practice to use a cryopreserved homograft in
patients who present with an infected aortic valve or root.
Homograft use is supported by the excellent results—
including mortality rates of 3.7% and 3.9%—reported by
Lytle and colleagues8 and Sabik and colleagues11 more
than a decade ago. Since then, there has been a paucity of
reports of homograft use in the United States, especially
in reoperated infected aortic roots, but it has been advocated
extensively in Europe.4,5 In the largest reported
contemporary homograft series, Musci and colleagues5
described their 20-year experience with 221 patients who
underwent homograft aortic root replacement for
endocarditis of the native (n ¼ 99) or prosthetic (n ¼ 122)
aortic valve. Early (30-day) mortality in the prosthetic valve
endocarditis group was 25.4%; 29.1% of the deaths were
intraoperative. The investigators noticed that 30-day
mortality was substantially lower in their native-valve
endocarditis group (16.1%; 6.2% of these deaths were
intraoperative).
In our group of 39 patients, all of whom had reoperations,
in-hospital mortality was 10.3% (n ¼ 4), including 1
intraoperative death. Our mortality rate is similar to the
11% rate reported by Hagl and colleagues6 from the Mount992 The Journal of Thoracic and Cardiovascular SurgSinai Group in New York. Only 3 of their 28 patients had
homograft placement; the rest received a mechanical
composite valve graft. Most other reports that include a
mix of prosthetic and biologic valve conduits show higher
mortality rates, especially in reoperative patients,7,12-14
such as those included in our study. Compared with the
patients in the Cleveland Clinic series,8 the patients in the
current series had higher mortality. This could be explained
by the fact that the percentage of patients who required
circulatory arrest for additional proximal arch or total
arch replacement was higher in our series (54% vs
15%).8 In addition, the permanent stroke rate among
survivors in our study was 2.6% (n¼ 1), which is somewhat
lower than the rates reported by others.7,9
During themedian follow-up of 2.4 years (range, 1 month
to 12.3 years), our patients, who all received homografts,
had 100% freedom from reinfection. In comparison, the
University of Pennsylvania group reported that for patients
who received mechanical conduits, biological conduits, and
homograft roots, freedom from reinfection was 84% 7%,
94%  4%, and 75%  11%, respectively, at 1 year and
74%  10%, 89%  6%, and 64%  14%, respectively,
at 5 years.7 David and coworkers12 reported that freedom
from recurrent infective endocarditis was 91%  2% at 5
years for all patients (native and prosthetic valve) and
84%  4% and 90%  4% at 15 years for patients treated
for native and prosthetic endocarditis, respectively. In their
study, few patients (18/261 patients [6.9%] with aortic
valve replacement) received a homograft; most patients
received a mechanical valve or conduit. The authors
concluded that the type of valve had no effect on the risk
of recurrent endocarditis, and they emphasized the
importance of radical debridement and implanting a new
valve on healthy and strong tissue.12 Reinfection rates of
5.4% and 3.7% were observed by Musci and colleagues5
and Lytle and al,8 respectively. Leontyev et al15 reported
that their 172 patients (including 76 who had reoperation)
had a 5-year freedom from recurrent endocarditis of 80%
 4%. None of the patients who received a homograft
(n ¼ 13, 7.5%) had recurrent endocarditis.15 The authors
stated that they were unable to show a statistically
significant effect of implanted valve type on recurrent
infection. A review by Perrotta and Lentini10 found that
using a stentless bioprosthesis resulted in the same low
reinfection rate as when using cryopreserved homografts.
Our series was not intended to compare bioprosthetic valves
or homografts with mechanical valves. We encountered no
reinfection, which we attribute to aggressive debridement
and the use of homograft tissue.
Only 1 patient among the 34 survivors in our series
(2.9%) required reoperation for structural deterioration
during our follow-up. This patient developed severe aortic
stenosis at 10 years, and he required a bioprosthetic valve
and a supracoronary aortic graft. Ten-year freedom fromery c September 2014
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Dreoperation was 89%  2% as reported by David and
colleagues12 in their series of 383 patients with mechanical
(n ¼ 214), bioprosthetic (n ¼ 133), and homograft valves
(n ¼ 18). The Stanford group9 reported that freedom from
reoperation in patients with mechanical valves was 74%
 9% at 10 years and 74%  9% at 15 years; they noticed
a decline in the freedom from reoperation by the 10th year
for patients who had bioprosthetic valves (56%  5% at
10 years, 22%  6% at 15 years, P > .64). In their
bioprosthetic group, the indication for reoperation was
structural degeneration in 63% of patients. For patients
aged more than 60 years, the freedom from reoperation
was acceptable after mechanical-valve or bioprosthesis
implantation, but for younger patients, the freedom from
reoperation after bioprosthesis implantation was low
(51%  5% at 10 years). In Musci and colleagues’5 series
of homograft operations for native and prosthetic valve en-
docarditis, the 1-, 5-, and 10-year freedom from reoperation
was 91.5%  4.7%, 79.8%  7.7%, and 79.8%  7.7%,
respectively, for patients aged less than 40 years (n ¼ 46);
95.6%  2.5%, 91.8%  3.5%, and 84.4%  5.2%,
respectively, for patients aged 40 to 60 years (n ¼ 97);
and 96.5%  2.4%, 92.9%  4.2%, and 88.7% 
5.8%, respectively, for patients aged more than 60 years.
With regard to complete heart block after surgery, 15.4%
of our patients required pacemakers. In comparison, the rate
of permanent pacemaker implantation among reoperative
patients was 37% in Lytle and colleagues’8 series and
19.7% in Leontyev and colleagues’15 series. Thus, the
need for pacemaker implantation to treat postoperative
complete heart block is common among these high-risk
patients. It is not specific to the aortic conduit used but is
associated with more extensive disease and the need for
extensive debridement.
Concerns regarding the technical complexity of the
initial operation, the availability of homograft tissue, and
the potential need for reoperation on a severely calcified
homograft have led several investigators to prefer
mechanical or nonhomograft biologic roots.6,9,12 In
contrast, because reinfection can pose complex and
challenging problems, we place greater emphasis on
reinfection-free survival than on the long-term risk of
reoperation; thus, we favor homografts over these other
options. It is possible that the risks posed by structural
deterioration of the valve in a homograft root will
increasingly be ameliorated as the use of transcatheter
aortic valve implantation becomes more common.16-18
Study Limitations
The limitations of our study include the small number of
patients, although, to our knowledge, ours is one of the
largest reported studies in North America. Also, the
retrospective and nonrandomized design of this study
makes it subject to interpretation bias. We did not attemptThe Journal of Thoracic and Cato make this a comparative study. The availability of the
homograft conduit at our institution may have affected
our decision to make it our conduit of choice in cases of
prosthetic root endocarditis and proximal aortic infection.
CONCLUSIONS
The use of homograft material to replace the aortic root,
the ascending aorta, and the arch in patients with
reoperative endocarditis can result in acceptable early
and midterm survival and a low reinfection rate.
Aggressive debridement is important to long-term survival
without reinfection. Structural degeneration, which was
uncommon in our patients, is even less of a concern
today because percutaneous valve technology is now
commercially available. Long-term follow-up is important
in this high-risk patient population.
Stephen N. Palmer, PhD, ELS, contributed to the editing of the
article.
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